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Abstract
Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disorder of the central nervous system, caused by the reacti-
vation of the ubiquitous JC virus. PML usually occurs during severe immunosuppression, and the most common causes are represented
by human immunodeﬁciency virus infection, lymphoproliferative disorders and other forms of cancer. Recently, the introduction of
monoclonal antibodies (e.g. natalizumab, rituximab, efalizumab) in the treatment of several dysimmune diseases such as multiple sclero-
sis, rheumatoid arthritis, psoriasis and systemic lupus erythematosus, has led to an increased incidence of PML. This phenomenon has
had severe consequences, leading, for example, to the withdrawal from the market of Efalizumab, and important restrictions in the use
of the other compounds, all of which are characterized by high efﬁcacy in improving prognosis and quality of life. In this review we will
discuss clinical, laboratory and imaging ﬁndings of PML. In addition, proposed pathogenetic mechanisms promoting the reactivation of JC
virus in the context of treatment with monoclonal antibodies will be described.
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Introduction
The deﬁnition ‘Progressive Multifocal Leukoencephalopathy’
(PML) was ﬁrst used in 1958 to describe a fatal demyelinating
central nervous system (CNS) disease in patients with lym-
phoproliferative disorders [1]. In 1971, the virus responsible
for the disease was isolated and named JC virus (JCV) after
the initials of the patient from whom the virus was ﬁrst iso-
lated [2]. After 40 years, several aspects of the disease are
well known but many questions regarding the pathogenesis
remain unanswered and no effective treatment is available. In
the pre-human immunodeﬁciency virus era PML was anec-
dotally reported in some patients with myelolymphoprolifer-
ative disorders or other forms of cancer, but its incidence
signiﬁcantly increased with the advent of acquired immuno-
deﬁciency syndrome, affecting 0.7/1000 persons/year [3].
After the introduction of antiretroviral treatment the inci-
dence (0.07/1000 persons/year) [3] and the mortality of the
disease reduced signiﬁcantly [4,5]. Recently, several cases of
PML related to the use of new immunomodulatory com-
pounds for the treatment of several dysimmune diseases
were reported, leading to an urgent need for the identiﬁca-
tion of risk factors and disease biomarkers.
Pathogenesis
JC virus is a double-stranded, circular DNA virus and a
member of the Polyomaviridae family. The viral genome
encodes six viral proteins, including two early regulatory
regions (small and large T antigens), another regulatory pro-
tein acting as a viroporin (agnoprotein) and the capsid pro-
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teins (VP1, VP2 and VP3) (Fig. 1). The presence of rearrange-
ments in the highly variable non-coding control region char-
acterizes the so-called Mad-1 type strain, neurotropic and
pathogenic, which probably derives from the non-pathogenic
archetype, detected in kidneys and tonsils.
There are two main hypotheses regarding the route of
primary infection, involving either upper respiratory tract
through inhalation or the gastrointestinal tract through inges-
tion of contaminated food and water. The ﬁnding of JCV in
tonsils seems to support the former hypothesis [6], but the
virus has also been detected in epithelial cells from the gas-
trointestinal tract [7,8] and in the oesophagus [9]. However,
as JCV can infect circulating B lymphocytes, both tonsils and
gastrointestinal tract may represent a site of latency rather
than the entry route of the virus. After the primary asymp-
tomatic infection, which is thought to occur in childhood,
the virus remains latent in different sites, including kid-
ney—as demonstrated by the shedding of virus in the urine
of 30% of immunocompetent subjects [10]—bone marrow
[11], B lymphocytes [12] and tonsils [6]. There is recent evi-
dence that the virus enters the brain from the early phases
of infection and establishes a non-productive or low-chronic
infection of glial cells [13,14]. Under particular conditions,
usually associated with severe immunosuppression, JCV can
actively replicate into the brain, leading to PML. The site and
modality of JCV reactivation are still poorly understood but
the most likely hypothesis is that the virus reactivates some-
where in the periphery and crosses the blood–brain barrier
through circulating infected cells, such as B lymphocytes,
entering the CNS where it infects astrocytes and promotes
lysis of oligodendrocytes with a consequent massive demye-
lination, predominantly involving white matter.
Clinical Findings
The classic form of PML has a fulminating evolution usually
leading to death within a few months. The onset is usually
multisymptomatic and the most common clinical presentation
includes motor deﬁcits, altered consciousness, gait ataxia and
visual symptoms. Atypical presentations, usually reported in
human immunodeﬁciency virus-infected patients after the
introduction of combination antiretroviral therapy, include
pure cerebellar syndrome, reﬂecting a productive infection of
granule cell neurons [15], meningitis [16], meningoencephalitis
[17,18], progressive myoclonic ataxia [19] and muscle wasting
associated with extrapyramidal signs [20].
Histopathological and Imaging Findings
Histopathology ﬁndings are typically represented by demyelin-
ation, enlarged oligodendrocytes productively infected by the
virus as demonstrated by appropriate staining, and bizarre as-
trocytes [21]. Foamy macrophages may be found at the
advancing edge of the lesions, actively involved in the removal
of myelin breakdown products [22]. Inﬂammation is usually
little or absent. Conventional magnetic resonance imaging
shows an extensive involvement of white matter, with multi-
focal, bilateral, asymmetrical lesions that appear hyperintense
in T2-weighted sequences and hypointense in T1-weighted
sequences (Fig. 2). The pathogenetic process starts from the
subcortical white matter and evolves towards the deep peri-
ventricular regions, involving also thalamus and basal ganglia,
with coalescence of lesions in the mid-to-late stage [23]. Pari-
eto-occipital lobes are preferentially involved [24]. Infratento-
rial white matter is frequently affected, with lesions located in
the middle cerebellar peduncles and adjacent regions, e.g.
pons and mid-cerebellum [25]. As inﬂammation is uncommon,
oedema and contrast enhancement are atypical ﬁndings.
Laboratory Findings
The diagnostic criteria recently proposed require the detec-
tion of the virus in cerebrospinal ﬂuid by PCR [22]. The
sensitivity of this laboratory technique was 72–92% in the
FIG. 1. JC virus circular DNA encodes for early transcripts, includ-
ing small and large T antigen and for late proteins (capsid proteins
VP1, VP2, VP3 and agnoprotein).
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era before combination antiretroviral therapy, with a speci-
ﬁcity of 92–100% but this fell markedly after the introduction
of antiretroviral drugs [26]. It is important, therefore, to
underline that even when JCV is undetectable in cerebrospi-
nal ﬂuid, the diagnosis of PML should not be excluded in
cases with clinical and magnetic resonance imaging ﬁndings
strongly compatible with the disease, and lumbar puncture
should be repeated over time and brain biopsy should even-
tually be taken into consideration.
PML and Immunomodulatory Treatments
In 2005 the ﬁrst three cases of PML in patients treated with
natalizumab were reported (two with multiple sclerosis and
one with Crohn’s disease) [27–29]. Since then, PML has been
described as an unexpected complication of different novel
immunomodulatory therapies used in dysimmune diseases,
such as natalizumab, efalizumab, rituximab and alemtuzumab.
We here review epidemiological and clinical data on the
occurrence of PML in patients treated with the ﬁrst three
compounds, and hypotheses on the related pathogenetic
mechanisms.
Natalizumab is a humanized monoclonal antibody directed
against the cellular adhesion molecule a4-integrin, which facil-
itates the entry of inﬂammatory cells into the CNS [30]. This
mechanism has a beneﬁcial role in multiple sclerosis reducing
the inﬂammatory inﬁltrates responsible for lesion formation,
but on the other hand it impedes immune surveillance across
the blood–brain barrier, with a reduction of the
CD4+ : CD8+ T-cell ratio within the CNS [31] that might
facilitate the occurrence of PML, especially considering that
glial cells are believed to represent a site of viral latency.
Other hypotheses on the pathogenesis of PML in patients
treated with natalizumab include the mobilization of infected
B cells and peripheral haematopoietic progenitor cells.
CD34+ facilitated by the blockage of a4-integrin plays an
important role in sequestering these cells in lymph nodes
and bone marrow. Recently, though, Warnke et al. [32] did
not ﬁnd JCV in CD34+ progenitor cells or peripheral mono-
nuclear blood cells of 67 patients with multiple sclerosis
treated with natalizumab, weakening the aforementioned
hypothesis.
After the ﬁrst PML cases natalizumab was brieﬂy with-
drawn from the market for safety concerns but was rapidly
brought back on the market for its evident beneﬁcial effects
on multiple sclerosis evolution. Since its reintroduction, 102
cases of PML have been reported from Biogen idec as of 4
March 2011 (55 in the USA, 42 in the European Union and
ﬁve in other areas) (data on ﬁle; Biogen Idec, https://medinfo.
elan.com/pdfs/220.pdf), with an overall incidence of 1.23/
1000 patients. The incidence is not stable over time but it
depends on the treatment duration, with a rate of 1.87
cases/1000 patients on the drug for a year or longer, rising
to 2.41/1000 for those on the drug for 2 years or longer,
and dropping to 1.4 for those on the drug for more than
3 years. At present, the beneﬁcial effects of the drug are
considered signiﬁcantly greater than the risk of PML, but
multiple sclerosis patients need to satisfy strict eligibility cri-
teria and are carefully monitored for the duration of the
treatment.
So far, the search for risk factors or early biomarkers of
disease has not been conclusive: viruria, viraemia and levels
of anti-JCV antibodies have given conﬂicting results, probably
because of the use of different assays and the fact that JCV
is widely diffused, regularly shed in urine and detected in the
blood of immunocompetent subjects. Although some authors
[33,34] did not detect any increase in plasma viraemia in
patients treated with natalizumab, others [35] reported
higher JCV infection in peripheral mononuclear blood cells
compared with plasma.
The research in this area is active and some clinical trials
are ongoing, assessing new and more sensitive assays to
detect any change in JCV replication and immune system
activation and seeking reliable biomarkers.
Efalizumab, analogous to natalizumab, inhibits T-cell adhe-
sion and diapedesis from the circulation [36]. It is a recombi-
nant humanized monoclonal IgG1 antibody directed against
the CD11a subunit of leukocyte function-associated antigen-
1 expressed on T cells, B cells and monocytes, approved by
FIG. 2. Axial FLAIR sequence of the brain showing hyperintense,
multifocal, bilateral asymmetrical lesions of the white matter, mainly
involving the posterior regions (reproduced with the courtesy of
Prof. S. Bastianello).
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the Food and Drug Administration in 2003 for the treatment
of moderate-to-severe chronic plaque psoriasis. In 2009 the
drug was withdrawn from the market because of the occur-
rence of three cases of PML out of more than 46 000 trea-
ted patients [37].
The occurrence of PML in relationship with compounds
that limit the access of T lymphocytes to the CNS underlines
the importance of the cellular component of the immune
system in the control of JCV replication within the brain.
Interesting information on the pathogenesis of the dis-
ease indirectly comes from the analysis of PML associated
with the use of rituximab, a chimeric IgG1 that links to
CD20 inducing a severe depletion of B lymphocytes. This
monoclonal antibody was approved in the USA in 1997 for
the treatment of non-Hodgkin’s lymphoma and is now mar-
keted also for rheumatoid arthritis, chronic lymphatic leu-
kaemia and as an off-label treatment in other diseases such
as systemic lupus erythematosus. At present, more than 70
cases of PML have been associated with the use of ritux-
imab [38–41], predominantly in patients with lymphoprolif-
erative disorders. The risk quantiﬁcation of PML related to
the use of rituximab is difﬁcult because PML has been
described in systemic lupus erythematosus, rheumatoid
arthritis, lymphoma and leukaemia independently from the
use of any treatment.
The occurrence of PML in the context of B-lymphocyte
depletion suggests not only that B cells are not the principal
vehicle for JCV to enter the brain, but also that humoral
immunity might play a role in the control of JCV replication,
as suggested by the description of PML in patients with con-
genital deﬁciency of humoral immunity [42]. On the other
hand, B-cell depletion may impact on T-cell activity, which is
known to be important in the control of JCV replication,
and may stimulate the proliferation and redistribution of
infected pre-B lymphocytes from the bone marrow to the
bloodstream, favouring viral entry into the CNS.
Although the use of these drugs has raised signiﬁcant
safety concerns, rituximab and natalizumab have been shown
to be very effective and drastically change the disease course.
Hence, the American and European regulatory agencies, after
a careful re-evaluation of the beneﬁt : risk ratio, decided to
not withdraw the drugs from the market and, instead, to
deﬁne strict eligibility criteria and put effort into creating
management guidelines in the case of PML occurrence. These
guidelines, together with the identiﬁcation of risk factors for
JCV reactivation and early biomarkers, should help to
identify the eligible patients with a consequent reduction of
PML occurrence and improvement in the management of the
disease.
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